Watch our Industry User Meeting from SNMMI's 2021 Annual Meeting!

We are an emerging leader with new solutions in the field of nuclear medicine technology

Our innovative products and technologies are designed to meet current and future demands for medical radioisotopes. They mark a new era for nuclear medicine technology.

Discover our Products

Supply

Medical radioisotopes are critical to meet patient healthcare needs and advance clinical research. We’ve charted the course for producing a stable, reliable and domestically sourced isotope supply.

Explore our Processes

Commitment

Our people drive our solutions. From providing domestic supply of isotopes for patients to national security and environmental sustainability, we are committed to advancing radioisotope technology to shape a better world.

Learn More

About NorthStar

We are a nuclear medicine technology company committed to providing the United States with stable, domestic and environmentally friendly radioisotope supply solutions to meet the needs of patients and advance clinical research. Our innovative technologies have the ability to fundamentally transform the ways that medical radioisotopes are produced and distributed around the world.

Learn More About NorthStar

Inside NorthStar

September 8, 2021

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

BELOIT, Wis. and INDIANAPOLIS, Ind., September 8, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc.

Press Releases

September 8, 2021

NorthStar Medical Radioisotopes to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference

BELOIT, Wis., September 8, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present at the H.C.

Press Releases

August 30, 2021

U.S. Department of Energy’s National Nuclear Security Administration Awards NorthStar Medical Radioisotopes $37 Million in Cooperative Agreement Funds to Further Domestic Molybdenum-99 (Mo-99) Production

− Supports neutron capture and accelerator production technology to further increase NorthStar’s production capacity of commercially available non-uranium based Mo-99 − BELOIT, Wis.,

How Can We Help?

Questions about company, products, supply solutions, careers or anything else?